Jim Kastenmayer
General Counsel bei ARRIVENT BIOPHARMA, INC.
Vermögen: 114 778 $ am 30.04.2024
Profil
Jim Kastenmayer is currently the Secretary & General Counsel at Arrivent BioPharma, Inc. He previously worked as the Legal Director & Senior Patent Director at AstraZeneca PLC from 2012 to 2019.
He also worked as the Secretary & General Counsel at Spyre Therapeutics, Inc. from 2021 to 2023 and at Viela Bio, Inc. from 2020 to 2021.
Additionally, he worked as an IP Counsel at Medimmune, Inc. Dr. Kastenmayer holds a doctorate degree from Michigan State University, an undergraduate degree from the University of Virginia, and a graduate degree from Georgetown University Law Center.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ARRIVENT BIOPHARMA, INC.
0,02% | 25.01.2024 | 7 386 ( 0,02% ) | 114 778 $ | 30.04.2024 |
Aktive Positionen von Jim Kastenmayer
| Unternehmen | Position | Beginn |
|---|---|---|
| ARRIVENT BIOPHARMA, INC. | General Counsel | 01.09.2023 |
Ehemalige bekannte Positionen von Jim Kastenmayer
| Unternehmen | Position | Ende |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Vorstandsvorsitzender | 29.11.2022 |
| VIELA BIO, INC. | General Counsel | 01.03.2021 |
| ASTRAZENECA PLC | General Counsel | 01.12.2019 |
| Medimmune, Inc. | Corporate Officer/Principal | - |
Ausbildung von Jim Kastenmayer
| Georgetown University Law Center | Graduate Degree |
| Michigan State University | Doctorate Degree |
| University of Virginia | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| SPYRE THERAPEUTICS, INC. | Health Technology |
| ARRIVENT BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
| Medimmune, Inc. | Health Technology |
